2. Inhibitory Antibodies
  3. Biosimilar Antibodies
  4. Monoclonal Antibodies

Monoclonal Antibodies

Monoclonal antibodies (mAbs) are highly homogeneous antibodies produced by a single B-cell clone that are directed only against a specific antigenic epitope and specifically bind to unique epitopes on targets such as pathogens and cancer cells. Monoclonal antibody drugs have been widely marketed and applied in clinics worldwide, helping countless patients to improve their survival rate and quality of life.

Monoclonal Antibodies (1701):

Cat. No. Product Name Purity  
  • HY-P9907
    Trastuzumab 99.80%  
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 44 : 78.)
  • HY-P9905
    Cetuximab 99.70%  
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
  • HY-P9906
    Bevacizumab ≥99.0%  
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-P9902
    Pembrolizumab 99.17%  
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P9904
    Atezolizumab 99.50%  
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P99058
    Zolbetuximab 98.10%  
    Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
  • HY-P9S0008
    Cetuximab (PBS)  
    Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect.
  • HY-P990941
    Rinatabart 99.47%  
    HY-P990941 is an FOLR1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P9926
    Dupilumab ≥99.2%  
    Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
  • HY-P9970
    Infliximab  
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
  • HY-P9913
    Rituximab 99.85%  
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
  • HY-P9903
    Nivolumab 99.63%  
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P9908
    Adalimumab 99.62%  
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P9917
    Tocilizumab 99.67%  
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
  • HY-P99045
    Sacituzumab 99.77%  
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
  • HY-P99355
    Bimagrumab 99.31%  
    Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
  • HY-P9915
    Daratumumab 99.10%  
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
  • HY-P990007
    Tulisokibart 99.00%  
    Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.
  • HY-P99055
    Urelumab 99.138%  
    Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).
  • HY-P99029
    Magrolimab 99.92%  
    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer.